梗死相关心源性休克临时机械循环支持:随机试验个体患者数据荟萃分析及6个月随访
该个体患者数据荟萃分析纳入9项随机对照试验报告(n=1114),比较早期常规活性经皮机械循环支持与对照治疗对急性心肌梗死相关心源性休克6个月全因死亡率的影响。结果显示,早期无选择使用机械循环支持未显著改善6个月死亡率(HR 0.87 [95%CI 0.74-1.03];p=0.10),左室卸载装置(HR 0.80 [95%CI 0.62-1.02];p=0.075)和加载装置(HR 0.93 [95%CI 0.75-1.17];p=0.55)均无显著效果。ST段抬高型心源性休克且无缺氧性脑损伤风险的患者使用机械循环支持死亡率降低(HR 0.77 [95%CI 0.61-0.97];p=0.024)。机械循环支持组大出血(OR 2.64 [95%CI 1.91-3.65])和血管并发症(OR 4.43 [95%CI 2.37-8.26])更常见。作者认为机械循环支持应仅限特定患者使用。
要点
- 在急性心肌梗死相关心源性休克患者中,早期常规活性机械循环支持未显著降低6个月全因死亡率(HR 0.87 [95%CI 0.74-1.03];p=0.10)。
- 左室卸载装置与对照相比6个月死亡率无显著差异(HR 0.80 [95%CI 0.62-1.02];p=0.075),加载装置亦无显著效果(HR 0.93 [95%CI 0.75-1.17];p=0.55)。
- ST段抬高型心源性休克且无缺氧性脑损伤风险的患者使用机械循环支持6个月死亡率降低(HR 0.77 [95%CI 0.61-0.97];p=0.024)。
- 机械循环支持组大出血风险增加(OR 2.64 [95%CI 1.91-3.65]),血管并发症风险增加(OR 4.43 [95%CI 2.37-8.26])。
- 作者认为机械循环支持应仅限特定患者使用。
适用人群与场景
- 急性心肌梗死相关心源性休克(AMICS)患者,来自9项随机对照试验报告(n=1114),中位年龄65岁(IQR 57-73),男性845/1058(79.9%),女性213/1058(20.1%)。
- 排除2项随机对照试验中非AMICS患者55例(VA-ECMO组44例,左室卸载装置组11例)。
研究设计与关键结果
- 研究类型:个体患者数据荟萃分析,纳入9项随机对照试验报告(n=1114),其中4项(n=611)比较VA-ECMO与对照,5项(n=503)比较左室卸载装置与对照;主要终点为6个月全因死亡率。
- 总体早期无选择机械循环支持 vs 对照:6个月全因死亡率无显著获益(HR 0.87 [95%CI 0.74-1.03];p=0.10)。
- 左室卸载装置 vs 对照:6个月死亡率无显著差异(HR 0.80 [95%CI 0.62-1.02];p=0.075)。
- 加载装置 vs 对照:6个月死亡率无显著效果(HR 0.93 [95%CI 0.75-1.17];p=0.55)。
- ST段抬高型心源性休克且无缺氧性脑损伤风险患者:机械循环支持组6个月死亡率降低(HR 0.77 [95%CI 0.61-0.97];p=0.024)。
- 安全性:机械循环支持组大出血(OR 2.64 [95%CI 1.91-3.65])和血管并发症(OR 4.43 [95%CI 2.37-8.26])较对照更常见。
证据类型、等级与局限
- 证据类型:个体患者数据荟萃分析(9项随机对照试验报告,n=1114),注册号PROSPERO CRD42024504295。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,机械循环支持应仅限特定患者使用;在AMICS患者中早期常规活性MCS未降低6个月死亡率,且增加大出血和血管并发症。
- 作者指出,ST段抬高型心源性休克且无缺氧性脑损伤风险的患者使用MCS后6个月死亡率降低(HR 0.77 [95%CI 0.61-0.97];p=0.024)。
指南或共识出处
- Lancet发表的个体患者数据荟萃分析(PROSPERO注册号CRD42024504295)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Percutaneous active mechanical circulatory support (MCS) devices are being increasingly used in the treatment of acute myocardial infarction-related cardiogenic shock (AMICS) despite conflicting evidence regarding their effect on mortality. We aimed to ascertain the effect of early routine active percutaneous MCS versus control treatment on 6-month all-cause mortality in patients with AMICS.
METHODS: In this individual patient data meta-analysis, randomised controlled trials of potential interest were identified, without language restriction, by querying the electronic databases MEDLINE via PubMed, Cochrane Central Register of Controlled Trials, and Embase, as well as ClinicalTrials.gov, up to Jan 26, 2024. All randomised trials with 6-month mortality data comparing early routine active MCS (directly in the catheterisation laboratory after randomisation) versus control in patients with AMICS were included. The primary outcome was 6-month all-cause mortality in patients with AMICS treated with early routine active percutaneous MCS versus control, with a focus on device type (loading, such as venoarterial extracorporeal membrane oxygenation [VA-ECMO] vs unloading) and patient selection. Hazard ratios (HRs) of the primary outcome measure were calculated using Cox regression models. This study is registered with PROSPERO, CRD42024504295.
FINDINGS: Nine reports of randomised controlled trials (n=1114 patients) were evaluated in detail. Overall, four randomised controlled trials (n=611 patients) compared VA-ECMO with a control treatment and five randomised controlled trials (n=503 patients) compared left ventricular unloading devices with a control treatment. Two randomised controlled trials also included patients who did not have AMICS, who were excluded (55 patients [44 who were treated with VA-ECMO and 11 who were treated with a left ventricular unloading device]). The median patient age was 65 years (IQR 57-73); 845 (79·9%) of 1058 patients with data were male and 213 (20·1%) were female. No significant benefit of early unselected MCS use on 6-month mortality was noted (HR 0·87 [95% CI 0·74-1·03]; p=0·10). No significant differences were observed for left ventricular unloading devices versus control (0·80 [0·62-1·02]; p=0·075), and loading devices also had no effect on mortality (0·93 [0·75-1·17]; p=0·55). Patients with ST-elevation cardiogenic shock without risk of hypoxic brain injury had a reduction in mortality with MCS use (0·77 [0·61-0·97]; p=0·024). Major bleeding (odds ratio 2·64 [95% CI 1·91-3·65]) and vascular complications (4·43 [2·37-8·26]) were more frequent with MCS use than with control.
INTERPRETATION: The use of active MCS devices in patients with AMICS did not reduce 6-month mortality (regardless of the device used) and increased major bleeding and vascular complications. However, patients with ST-elevation cardiogenic shock without risk of hypoxic brain injury had a reduction in mortality after MCS use. Therefore, the use of MCS should be restricted to certain patients only.
FUNDING: The Heart Center Leipzig at Leipzig University and the Foundation Institut für Herzinfarktforschung.
参考来源
- Thiele H, Møller JE, Henriques JPS, et al. Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up. Lancet. 2024. PMID: 39236726. doi:10.1016/S0140-6736(24)01448-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。